IP Library Granted Patent US 10,947,539
Granted Patent B2
US 10,947,539 · App. 16/268,814 · Granted Mar 16, 2021

Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides

Inventors: Bruce H. Littman (Stonington, CT); John F. Thompson (Warwick, RI); Frank W. Marcoux (Stonington, CT)
C12N15/1137A61K38/1709A61K38/45A61K38/465A61K38/47A61K38/482A61K38/51A61K39/05A61K47/645C07K14/4702C12N9/12C12N9/16C12N9/2402C12N9/6424C12N9/88C07K2319/01C07K2319/10C12N2310/3513C12Y207/1101C12Y301/06013C12Y302/01045C12Y302/01076C12Y304/21093C12Y406/01002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,947,539
App. No.
16/268,814
Granted
Mar 16, 2021
Kind
B2
Abstract

Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS. In various embodiments, the disclosed compositions are suitable for delivery into a cell (i) the expression product of a gene of interest and/or (ii) novel peptides or polynucleotides to regulate gene function.

Claims (3)

1. A cell-penetrating peptide conjugate consisting of SEQ ID No. 21.

2. The conjugate of claim 1 , wherein the conjugate interacts with an intracellular target and/or an intranuclear target.

3. A composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier.

Assignments (2)
CHANGE OF NAME Recorded Apr 2, 2021
From: PORTAGE PHARMACEUTICALS LTD.
To: PPL (BVI) LIMITED
Reel/Frame 055808/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2019
From: LITTMAN, BRUCE H.; THOMPSON, JOHN F.; MARCOUX, FRANK W.
To: PORTAGE PHARMACEUTICALS LTD.
Reel/Frame 049887/0946 →
Continuity (3)
Continuation 14897450
Provisional Application 61833819 · Jun 11, 2013
Related Publication 20190153450A1 · May 23, 2019